Dr Wallace Pickworth | Manipulating pH in Smokeless Tobacco: Unlocking the Chemistry of Addiction
Tobacco addiction remains a significant public health challenge, with millions of people using smokeless tobacco (SLT) products worldwide. Dr Wallace Pickworth from Battelle Life Sciences Research is investigating how the chemical properties of these products influence their addictiveness. His groundbreaking research has confirmed that the pH level of SLT and other oral tobacco products plays a crucial role in determining how quickly nicotine enters the bloodstream, with important implications for tobacco regulation and public health.
A Hidden Chemical Dance
When someone uses smokeless tobacco (SLT), they might not realise they’re participating in a complex chemical interaction. Nicotine, the addictive component in tobacco, exists in two forms: ‘free-base’ (unprotonated) and protonated. The proportion of each form depends largely on the product’s pH level – a measure of acidity or alkalinity.
This chemical state matters because only the free-base form of nicotine can easily cross the tissues in the mouth to enter the bloodstream. The higher the pH, the more free-base nicotine is available for absorption. Commercial SLT products show a wide range of pH levels, from quite acidic (pH 5.3) to quite alkaline (pH 8.4), suggesting that manufacturers may manipulate this characteristic to influence how quickly and effectively nicotine reaches the user.
The Hidden Dangers of Smokeless Tobacco
Nearly six million adults in the United States regularly use SLT, representing about 2.4% of the adult population. This seemingly small percentage translates into a significant public health concern, as regular use is associated with increased risks of various cancers, cardiovascular disease, and premature death. Further, many SLT users transition to combustible tobacco.
While most of tobacco’s harmful health effects come from components other than nicotine, it is nicotine that drives the addiction that keeps users coming back. Understanding how nicotine is delivered to the body has, therefore, become a crucial area of research in the fight against tobacco addiction.
A Novel Approach to Understanding Addiction
Previous studies had suggested a connection between pH levels and nicotine absorption, but other varying factors between products, such as tobacco cut, flavourings, and overall nicotine content, complicated these investigations. To truly understand the role of pH, researchers needed to isolate this single variable – a challenging task given the complex nature of tobacco products.
Dr Pickworth, working with colleagues at the University of Maryland School of Pharmacy and the US Food and Drug Administration, Center for Tobacco Products, took a single commercial product – Copenhagen Long Cut Original – and carefully modified it to create four versions identical in every way except their pH levels.
Addressing the Technical Challenge
Creating these experimental products proved to be a significant technical challenge. The team needed to ensure that only the pH changed while maintaining consistent levels of nicotine, moisture, and other components. They designed an innovative study to examine this relationship by creating four versions of the same SLT product that were identical in every way except their pH levels. This required careful modification of a popular commercial product using precise amounts of citric acid or sodium carbonate to achieve the desired pH values.
The team selected pH levels of 5.0, 7.7, 8.2, and 8.6, corresponding to free-base nicotine percentages of 0.1%, 32%, 60%, and 79% respectively. This range represented the spectrum found in commercial products while allowing the researchers to examine how different pH levels affected nicotine absorption.
The modified products underwent extensive stability testing over 19 months. This included regular measurements of pH, nicotine content, tobacco-specific nitrosamines (cancer-causing compounds), moisture levels, and even mould and yeast growth. This rigorous testing ensured
A Groundbreaking Clinical Study
Dr Pickworth recruited 40 regular SLT users for a carefully controlled study. Each participant tried all four products in random order across different sessions, keeping the tobacco in their mouth for exactly 30 minutes each time. The researchers collected blood samples before and after product use, tracking nicotine levels for four hours. They also monitored heart rate and blood pressure to understand how the body responded to different rates of nicotine absorption.
The results were remarkable in that the amount of nicotine absorbed varied dramatically based on the product’s pH level. The product with the highest pH (8.6) delivered more than four times as much nicotine into the bloodstream compared to the lowest pH product (5.0) despite containing the same amount of total nicotine. This was reflected in both the maximum concentration of nicotine in the blood and the total amount absorbed over time. The average maximum nicotine concentration in participants’ blood increased from 3.9 ng/ml with the pH 5.0 product to 16.7 ng/ml with the pH 8.6 product.
Interestingly, the relationship between pH and nicotine absorption wasn’t entirely straightforward. The team discovered that even at very low pH levels, some nicotine was still absorbed, likely due to the buffering effects of saliva. This highlighted the complex interplay between product chemistry and human physiology.
The study revealed that pH levels affected not just nicotine absorption but also physical responses. Products with higher pH levels led to greater increases in heart rate and blood pressure, though these changes were relatively modest. This demonstrated that the chemical properties of the product influenced both how much nicotine entered the body and its physiological effects.
The Body’s Response to Nicotine
The cardiovascular effects closely mirrored the nicotine absorption patterns. Products with higher pH levels caused larger increases in heart rate and blood pressure, though these changes remained within safe levels. For example, heart rate increased by nearly 9 beats per minute with the highest pH product but showed almost no change with the lowest pH version.
These cardiovascular changes provided clear evidence that pH levels influence not just how much nicotine enters the bloodstream but also how quickly the body responds to it. This speed of delivery is crucial for understanding addiction potential, as faster-acting drugs typically have a higher addiction risk.
Engineering Addiction Through pH Levels
This research has revealed how tobacco manufacturers can potentially manipulate a product’s addictiveness by adjusting its pH level. Products with higher pH levels deliver nicotine more quickly and efficiently, which could influence their addictive potential. This rapid delivery of nicotine is known to be an important factor in the development and maintenance of nicotine dependence.
Commercial SLT products currently available in the United States have pH levels ranging from 5.3 to 8.4, suggesting that some products may be significantly more addictive than others based on their pH alone. The implications of this pH variation are significant. A product’s pH level effectively controls what proportion of its nicotine content is available for rapid absorption. At pH 5.0, only 0.1% of nicotine is in the free-base form, while at pH 8.6, this rises to 79% – an 800-fold difference that dramatically affects how quickly users feel nicotine’s effects.
Implications for Public Health and Regulation
The findings suggest that considering only the total nicotine content of a product may be insufficient – the pH level plays a crucial role in determining how much of that nicotine actually reaches the user. Dr Pickworth and his colleagues are now advocating for both total nicotine content and pH levels to be considered in tobacco product regulation. Current approaches focusing primarily on nicotine content may be insufficient, as pH levels play such a crucial role in determining a product’s addictiveness.
The research also has implications beyond traditional SLT. New nicotine products, including pouches that contain nicotine but no tobacco, are becoming increasingly popular. These products often use pH manipulation to control nicotine delivery, making Dr Pickworth’s findings particularly relevant to their regulation.
This knowledge could influence how regulatory bodies approach SLT products. It also has implications for the development of less harmful nicotine delivery systems, where controlled absorption rates might help people transition away from more dangerous tobacco products.
Future Directions for Addiction Research
The research team’s innovative approach of studying one product characteristic in isolation could serve as a model for future research. Similar methods could be used to investigate how other product features – such as flavourings, tobacco cut, or moisture content – influence addiction and health risks.
Dr Pickworth has a continuing interest in how product characteristics influence nicotine delivery and addiction potential. The work may help inform the development of less addictive tobacco products while also providing crucial information for regulatory agencies.
As new tobacco and nicotine products continue to emerge, the insights from this research become increasingly valuable. Dr Pickworth’s work provides a crucial foundation for understanding how chemical properties influence addiction, potentially paving the way for more effective regulation and reduced public health impact from these products. By understanding these fundamental mechanisms of nicotine delivery, researchers and regulators can work more effectively to combat tobacco addiction and its devastating health consequences.
SHARE
DOWNLOAD E-BOOK
REFERENCE
https://doi.org/10.33548/SCIENTIA1143
MEET THE RESEARCHER
Dr Wallace B. Pickworth
Battelle Life Sciences Research, Baltimore, MD, USA
Dr Wallace Pickworth obtained his PhD in Pharmacology from the University of Tennessee in 1974. He has over 40 years of experience in preclinical and clinical research, including serving as the Principal Investigator (PI)/Senior Project Director on various projects for the National Institute on Drug Abuse, the private pharmaceutical industry, and as PI and co-investigator on extramural grants from the National Institutes of Health. At Battelle, Dr Pickworth is currently Research Leader, and specialises in clinical research on tobacco and nicotine. He has published extensively over the course of his career and has reviewed for a number of high-profile academic journals.
CONTACT
E: PickworthW@battelle.org; wpickworth@yahoo.com
W: https://www.battelle.org/
KEY COLLABORATORS
University of Maryland School of Pharmacy
U.S. Food and Drug Administration
Carson Smith, Battelle Memorial Institute
Jack Henningfield, Pinney Associates
Bartosz Koszowski, Pharmaron Inc.
FUNDING
U.S. Food and Drug Administration, Center for Tobacco Products
National Institutes of Health: National Cancer Institute, Heart Lung and Blood Institute
Battelle Memorial Institute (internal funds)
FURTHER READING
SW Hoag, EV Mishina, L Viray, et al., Formulation of smokeless tobacco products with a wide range of pH to study nicotine pharmacokinetics and pharmacodynamics, Pharmaceutical Development and Technology, 2022, 27(6), 646–653. DOI: https://doi.org/10.1080/10837450.2022.2102650
J Wilhelm, E Mishina, L Viray, et al., The pH of Smokeless Tobacco Determines Nicotine Buccal Absorption: Results of a Randomized Crossover Trial, Clinical Pharmacology and Therapeutics, 2022, 111(5), 1066–1074. DOI: https://doi.org/10.1002/cpt.2493
RV Fant, JE Henningfield, RA Nelson, WB Pickworth, Pharmacokinetics and pharmacodynamics of moist snuff in humans, Tobacco Control, 1999, 8(4), 387–392. DOI: https://doi.org/10.1136/tc.8.4.387
R Fant, WB Pickworth, JE Henningfield, The Addictive Effects of Nicotine Are Related to the Speed of Delivery, Nicotine as a Therapeutic Agent, Immunity and Environment, 1997, 10, 53–61.
REPUBLISH OUR ARTICLES
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence (CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License.
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
SUBSCRIBE NOW
Follow Us
MORE ARTICLES YOU MAY LIKE
Dr P Jacob Bueno de Mesquita | Germicidal Ultraviolet (GUV): A Powerful Tool for Improving Indoor Air Quality and Reducing Disease Transmission
The COVID-19 pandemic highlighted the critical importance of indoor air quality for public health. Dr P Jacob Bueno de Mesquita from Roger Williams University is part of a growing community of scientists dedicated to studying and implementing germicidal ultraviolet (GUV) technology to reduce the transmission of airborne pathogens. This work has the potential to dramatically improve air quality in indoor spaces and mitigate the spread of respiratory infections like COVID-19, influenza, RSV, common colds, and tuberculosis.
Dr Anna Robinson-Barella | Transforming Pharmacy Education and Practice to Create Culturally Competent Practitioners
There is a recognised need for healthcare professionals to provide culturally sensitive care. Dr Anna Robinson-Barella from the School of Pharmacy at Newcastle University is leading research working to integrate cultural competency training into pharmacy education and the pharmacy profession. Her studies reveal insights from both pharmacy staff and students on how best to equip the next generation of pharmacists with these vital skills. This work aims to transform pharmacy practice and reduce health inequalities for patients from diverse, minoritised backgrounds.
Dr Engelke Marie Randers – Dr Thomas Johan Kibsgård | Sacroiliac Joint Fusion: Upending Decades of Research
Sacroiliac joint fusion is a popular surgical procedure to address lower back pain. Despite this, a careful review of the literature shows that we have little solid evidence to confirm that the procedure is particularly effective at reducing pain. Dr Engelke Marie Randers and Dr Thomas Johan Kibsgård at the University of Oslo conducted a thorough trial to determine the real-world therapeutic benefit of this surgery – with important results.
Dr Patrick Wagner | Novel Approaches for Treating Advanced Abdominal Cancers
Metastatic abdominal cancers pose a unique set of challenges for clinicians. Dr Patrick Wagner from the Allegheny Health Network Cancer Institute is exploring important new ways to tackle these malignancies. With the help of his team, he carries out groundbreaking research into utilising the patient’s own immune system as well as exploring methods of drug delivery to fight these extremely challenging forms of cancer effectively.